[1] Guazzi M,Borlaug BA. Pulmonary hypertension due to left heart disease[J].Circulation,2012,126(8):975~990. [2] Craig B. Clark, DO, Evelyn M. Horn, et al. Group 2 pulmonary, hypertension pulmonary venous hypertension epidemiology and pathophysiology craig B[J].Cardiol Clin,2016,34(1):401~411. [3] Simonneau G ,Gatziulis MA, Adatia I,et al. Updated clinical classification of pulmonary hypertension[J].Am Coll Cardiol,2013,62(25):D34~D41. [4] Corte TJ,McDonagh TA,Wort SJ.Pulmonary hypertension in left heart disease:a review[J].Int Cardiol,2012;156( 3):253~258. [5] Richter B, L Koller PJ,Hohensinner G,et al.2013. A multi-biomarker risk score improves,prediction of long-term mortality in patients with advanced heart,failure[J].International Journal of Cardiology,168:1251~1257. [6] Nickel N, Kempf T,Tapken H. Growth Differentiation Factor-15 in Idiopathic Pulmonary Arterial Hypertension[J].Respiratory Research,2011,12:62. [7] Leuchte HH,Holzapfel M,Baumgartner RA,et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension[J].Am Coll Cardiol,2004,43(5):764~770. [8] Goto K,Arai M,Watanabe A,et al. Utility of echocardiography versus BNP level for the prediction of pulmonary arterial pressure in patients with pulmonary arterial hypertension[J].Int Heart,2010,51( 5):343~347. [9] Dentali F,Donadini M,Gianni M,et al. Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism[J].Intern Emerg Med,2009,4( 2):123~128. [10] Nagai T,Anzai T,Kaneko H.C-reactive prtein overexpression exacerbates pressure overload-induced cardiac remodeling through enhanced inflammatory response[J].Hypertension,2011,2:208~215. |